Investors

Welcome to Elicera's Investor Relations pages! Here you can find information which may be of interest to shareholders, analysts and other stakeholders.

If you need more information or have any questions, please contact Jamal El-Mosleh, CEO.
‍
Phone: +46(0)703 31 90 51
Email: info@elicera.com

Press Releases

June 11, 2025
Regulatory
Elicera Therapeutics postpones final reporting of ELC-100 study due to database transition
Read more
May 28, 2025
Regulatory
Elicera Therapeutics enters a Material Transfer Agreement with University Hospital Tübingen for testing of the company’s oncolytic virus candidates, ELC-100 and ELC-201
Read more
May 27, 2025
Regulatory
Elicera Therapeutics' CEO sells a small portion of his shareholding – remains a long-term major shareholder with strong confidence in the company’s future
Read more
All Press Releases

Corporate Governance

The following sections contain information that are relevant for Elicera's corporate governance.

Articles of AssociationGeneral MeetingBoardManagementAuditorCertified Adviser

The Share

Elicera Therapeutics is listed on Nasdaq First North Growth Market. The company has issued one class of shares and the total number of shares amounts to 19 782 000.

Read about the Share

Financial Reports

Front cover of an Elicera report
Latest report:
May 15, 2025
Q1 report 2025
All Financial Reports

Financial Calendar

See the calendar

Analyst Coverage

Read the latest analysis on Elicera here:

Penser Future (in Swedish)
All analyses
   
By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our Integrity policy.